CINCINNATI– CinRx Pharma, a mosaic of biotechnology companies accelerating transformational new medicines to patients, today announced that the first study participant has been dosed in CinDome Pharma’s Phase 2 envision3D study of deudomperidone (CIN-102) in patients with diabetic gastroparesis. Deudomperidone is a Dopamine 2/3 antagonist with prokinetic and antiemetic effects being evaluated for the chronic treatment of patients who currently have no therapeutic options for long term management. Gastroparesis is a syndrome defined by delayed gastric emptying in the absence of any physical obstruction and symptoms include bloating, nausea, vomiting, postprandial fullness, and early satiety.
“There are nearly 16 million people in the U.S. living with symptoms of gastroparesis, and many millions more worldwide, without a safe, well tolerated medicine that can be used for long term disease management,” explained Dr. Jon Isaacsohn, Founder and Chief Executive Officer of CinRx Pharma. “Deudomperidone is a novel formulation of domperidone which we have designed to overcome the limitations of existing therapies. Importantly, deudomperidone has been clinically tested to demonstrate its low risk of QT prolongation at therapeutic doses, and it does not readily cross the blood brain barrier enabling the extended use needed for management of chronic gastroparesis. We remain encouraged about the potential for deudomperidone to bring long-term relief to those suffering with this challenging condition.”
The Phase 2 envision3D study is a randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of deudomperidone in adults with diabetic gastroparesis after 12 weeks of treatment.
